Literature DB >> 28759386

Preventive therapy for cancer.

Jack Cuzick1.   

Abstract

Therapeutic cancer prevention is a developing area that can gain a lot from the successes in the prevention of cardiovascular diseases. Although weight control and physical activity are important in the prevention of both diseases, several other preventive measures exist. Low-dose aspirin for cancer prevention is often cited as the most important approach in terms of population benefit, and should be offered to those older than 50 years of age without hypertension or risk factors for gastrointestinal bleeding. Universal vaccination against the human papillomavirus, ideally with the nine-valent vaccine, also offers substantial benefits for the whole population if given before infection occurs (ie, typically at age 12-14 years). Other therapies, such as anti-oestrogen drugs for breast cancer prevention, should be targeted to high-risk groups to maintain a favourable benefit-risk ratio. Better algorithms for identification and improved platforms to reach these groups, such as during a screening visit, remain a key priority to allow existing knowledge to inform public health. Many other promising compounds have been identified, often as components of food, but results suggesting increased disease incidence with β carotene and vitamin E administration indicate that such treatments need rigorous evaluation before acceptance.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28759386     DOI: 10.1016/S1470-2045(17)30536-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  29 in total

1.  Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.

Authors:  Oleh Lushchak; Veronika Piskovatska; Olha Strilbytska; Iryna Kindrat; Nadya Stefanyshyn; Alexander Koliada; Volodymyr Bubalo; Kenneth B Storey; Alexander Vaiserman
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

Review 3.  Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

Authors:  Ismail Jatoi
Journal:  Eur J Breast Health       Date:  2018-10-01

Review 4.  Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.

Authors:  Jack Cuzick
Journal:  Br J Cancer       Date:  2018-04-23       Impact factor: 7.640

5.  A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion.

Authors:  Beatrice Malacrida; Sam Nichols; Eleni Maniati; Roanne Jones; Robin Delanie-Smith; Reza Roozitalab; Eleanor J Tyler; Morgan Thomas; Gina Boot; Jonas Mackerodt; Michelle Lockley; Martin M Knight; Frances R Balkwill; Oliver M T Pearce
Journal:  iScience       Date:  2021-05-29

6.  The relationship between chimeric RNAs and gene fusions: Potential implications of reciprocity in cancer.

Authors:  Justin Elfman; Lam-Phong Pham; Hui Li
Journal:  J Genet Genomics       Date:  2020-06-14       Impact factor: 5.723

7.  Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned.

Authors:  Justin de Brabander; Ferry A L M Eskens; Susanne E Korsse; Evelien Dekker; Pieter Dewint; Monique E van Leerdam; Susanne van Eeden; Heinz-Josef Klümpen
Journal:  Oncologist       Date:  2018-01-25

Review 8.  ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer.

Authors:  Heather M Bond; Stefania Scicchitano; Emanuela Chiarella; Nicola Amodio; Valeria Lucchino; Annamaria Aloisio; Ylenia Montalcini; Maria Mesuraca; Giovanni Morrone
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-18       Impact factor: 5.555

Review 9.  Melatonin: A Molecule for Reducing Breast Cancer Risk.

Authors:  Alicia González-González; María Dolores Mediavilla; Emilio J Sánchez-Barceló
Journal:  Molecules       Date:  2018-02-06       Impact factor: 4.411

10.  Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1.

Authors:  Verena Staedtke; Tyler Gray-Bethke; Gregory J Riggins; Ren-Yuan Bai
Journal:  Genes (Basel)       Date:  2020-07-08       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.